S&P 500   3,122.03 (+0.05%)
DOW   28,036.22 (+0.11%)
QQQ   203.07 (+0.08%)
AAPL   267.10 (+0.50%)
FB   197.40 (+1.18%)
MSFT   150.34 (+0.25%)
GOOGL   1,319.84 (-1.03%)
AMZN   1,752.53 (+0.75%)
CGC   14.22 (-7.24%)
NVDA   212.28 (+3.96%)
MU   47.82 (+0.23%)
BABA   184.61 (-0.47%)
GE   11.44 (-0.69%)
TSLA   349.99 (-0.62%)
T   39.63 (+0.33%)
AMD   39.88 (+3.42%)
ACB   2.28 (-16.48%)
F   8.95 (+0.00%)
PRI   131.10 (+0.37%)
NFLX   302.57 (+2.56%)
BAC   32.96 (+0.09%)
GILD   64.29 (-1.20%)
DIS   147.65 (+2.06%)
S&P 500   3,122.03 (+0.05%)
DOW   28,036.22 (+0.11%)
QQQ   203.07 (+0.08%)
AAPL   267.10 (+0.50%)
FB   197.40 (+1.18%)
MSFT   150.34 (+0.25%)
GOOGL   1,319.84 (-1.03%)
AMZN   1,752.53 (+0.75%)
CGC   14.22 (-7.24%)
NVDA   212.28 (+3.96%)
MU   47.82 (+0.23%)
BABA   184.61 (-0.47%)
GE   11.44 (-0.69%)
TSLA   349.99 (-0.62%)
T   39.63 (+0.33%)
AMD   39.88 (+3.42%)
ACB   2.28 (-16.48%)
F   8.95 (+0.00%)
PRI   131.10 (+0.37%)
NFLX   302.57 (+2.56%)
BAC   32.96 (+0.09%)
GILD   64.29 (-1.20%)
DIS   147.65 (+2.06%)
S&P 500   3,122.03 (+0.05%)
DOW   28,036.22 (+0.11%)
QQQ   203.07 (+0.08%)
AAPL   267.10 (+0.50%)
FB   197.40 (+1.18%)
MSFT   150.34 (+0.25%)
GOOGL   1,319.84 (-1.03%)
AMZN   1,752.53 (+0.75%)
CGC   14.22 (-7.24%)
NVDA   212.28 (+3.96%)
MU   47.82 (+0.23%)
BABA   184.61 (-0.47%)
GE   11.44 (-0.69%)
TSLA   349.99 (-0.62%)
T   39.63 (+0.33%)
AMD   39.88 (+3.42%)
ACB   2.28 (-16.48%)
F   8.95 (+0.00%)
PRI   131.10 (+0.37%)
NFLX   302.57 (+2.56%)
BAC   32.96 (+0.09%)
GILD   64.29 (-1.20%)
DIS   147.65 (+2.06%)
S&P 500   3,122.03 (+0.05%)
DOW   28,036.22 (+0.11%)
QQQ   203.07 (+0.08%)
AAPL   267.10 (+0.50%)
FB   197.40 (+1.18%)
MSFT   150.34 (+0.25%)
GOOGL   1,319.84 (-1.03%)
AMZN   1,752.53 (+0.75%)
CGC   14.22 (-7.24%)
NVDA   212.28 (+3.96%)
MU   47.82 (+0.23%)
BABA   184.61 (-0.47%)
GE   11.44 (-0.69%)
TSLA   349.99 (-0.62%)
T   39.63 (+0.33%)
AMD   39.88 (+3.42%)
ACB   2.28 (-16.48%)
F   8.95 (+0.00%)
PRI   131.10 (+0.37%)
NFLX   302.57 (+2.56%)
BAC   32.96 (+0.09%)
GILD   64.29 (-1.20%)
DIS   147.65 (+2.06%)
Log in

Intec Pharma Stock Price, Forecast & Analysis (NASDAQ:NTEC)

$0.49
-0.01 (-2.00 %)
(As of 11/18/2019 04:00 PM ET)
Today's Range
$0.48
Now: $0.49
$0.50
50-Day Range
$0.49
MA: $0.70
$0.85
52-Week Range
$0.41
Now: $0.49
$9.25
Volume208,900 shs
Average Volume944,206 shs
Market Capitalization$16.08 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.01
Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NTEC
CUSIPN/A
Phone972-2586-4657

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.53 per share

Profitability

Net Income$-43,540,000.00

Miscellaneous

Employees70
Market Cap$16.08 million
Next Earnings Date2/26/2020 (Estimated)
OptionableOptionable

Receive NTEC News and Ratings via Email

Sign-up to receive the latest news and ratings for NTEC and its competitors with MarketBeat's FREE daily newsletter.


Intec Pharma (NASDAQ:NTEC) Frequently Asked Questions

What is Intec Pharma's stock symbol?

Intec Pharma trades on the NASDAQ under the ticker symbol "NTEC."

How were Intec Pharma's earnings last quarter?

Intec Pharma Ltd (NASDAQ:NTEC) announced its earnings results on Tuesday, November, 12th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.22) by $0.10. View Intec Pharma's Earnings History.

When is Intec Pharma's next earnings date?

Intec Pharma is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Intec Pharma.

What price target have analysts set for NTEC?

5 brokers have issued 1-year target prices for Intec Pharma's shares. Their forecasts range from $1.00 to $16.00. On average, they expect Intec Pharma's share price to reach $11.80 in the next year. This suggests a possible upside of 2,308.2% from the stock's current price. View Analyst Price Targets for Intec Pharma.

What is the consensus analysts' recommendation for Intec Pharma?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intec Pharma in the last year. There are currently 5 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Intec Pharma.

What are Wall Street analysts saying about Intec Pharma stock?

Here are some recent quotes from research analysts about Intec Pharma stock:
  • 1. According to Zacks Investment Research, "Intec Pharma Ltd. is a biopharmaceutical company. The company focused on developing drugs through proprietary Accordion Pill platform technology. Its product candidates in clinical trial stages consists of Accordion Pill Carbidopa/Levodopa developed for the indication of treatment of Parkinson's disease symptoms; Accordion Pill Zaleplon is being developed for the indication of treatment of insomnia, including sleep induction and the improvement of sleep maintenance. Intec Pharma Ltd. is based in JERUSALEM, Israel. " (10/16/2019)
  • 2. LADENBURG THALM/SH SH analysts commented, "We are modeling mid-’19 cash is sufficient to fund operations till late 2020. While we appreciate Accordion Pill’s controlled-release abilities and still find AP-CBD/THC’s PK results vs. Sativex as impressive (290-330% and 25-50% higher exposures of CBD and THC, respectively, than Sativex), we have little insight into how the AP-Novartis Phase 1 may come out. Intec’s collaboration on an undisclosed compound was announced. Intec reported it successfully developed an a proprietary Novartis compound that met the prerequisite in vitro specifications. In 1Q’19 a human PK began, with the expectation for completion of the study and the results this summer, with Novartis making a go/no-go decision on a Phase 2 this fall." (8/12/2019)
  • 3. Maxim Group analysts commented, "Intec announced the presentation of the results from its PK study on AP-CD/ LD (Accordion Pill – Carbidopa/Levodopa) in Parkinson’s disease (PD) at the XXIV Related Disorders. The data was originally reported on 2/19 (see note, LINK), however, additional detail was provided in the presentation." (6/20/2019)

Has Intec Pharma been receiving favorable news coverage?

News articles about NTEC stock have been trending neutral this week, according to InfoTrie. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Intec Pharma earned a news sentiment score of 0.3 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Intec Pharma.

Are investors shorting Intec Pharma?

Intec Pharma saw a decrease in short interest in October. As of October 31st, there was short interest totalling 901,800 shares, a decrease of 31.2% from the September 30th total of 1,310,000 shares. Based on an average trading volume of 1,780,000 shares, the days-to-cover ratio is currently 0.5 days. Approximately 3.1% of the shares of the stock are short sold. View Intec Pharma's Current Options Chain.

Who are some of Intec Pharma's key competitors?

What other stocks do shareholders of Intec Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intec Pharma investors own include Viking Therapeutics (VKTX), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP), Verastem (VSTM), Intel (INTC), SCYNEXIS (SCYX), Zynerba Pharmaceuticals (ZYNE), AbbVie (ABBV), Amarin (AMRN) and Catalyst Pharmaceuticals (CPRX).

Who are Intec Pharma's key executives?

Intec Pharma's management team includes the folowing people:
  • Mr. Jeffrey A. Meckler, Vice Chairman & CEO (Age 52)
  • Mr. Nir Sassi, Chief Financial Officer (Age 43)
  • Dr. Nadav Navon Ph.D., Chief Operating Officer (Age 50)
  • Mr. Walt Addison Linscott, Chief Bus. Officer (Age 58)
  • Dr. R. Michael Gendreau, Chief Medical Officer (Age 63)

When did Intec Pharma IPO?

(NTEC) raised $30 million in an IPO on Tuesday, August 4th 2015. The company issued 5,000,000 shares at a price of $6.00 per share. Maxim Group and Roth Capital Partners served as the underwriters for the IPO.

Who are Intec Pharma's major shareholders?

Intec Pharma's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Harel Insurance Investments & Financial Services Ltd. (1.62%) and Taylor Frigon Capital Management LLC (1.26%). Company insiders that own Intec Pharma stock include Anthony J Maddaluna and Jeffrey A Meckler. View Institutional Ownership Trends for Intec Pharma.

Which major investors are selling Intec Pharma stock?

NTEC stock was sold by a variety of institutional investors in the last quarter, including Harel Insurance Investments & Financial Services Ltd.. View Insider Buying and Selling for Intec Pharma.

Which major investors are buying Intec Pharma stock?

NTEC stock was acquired by a variety of institutional investors in the last quarter, including Taylor Frigon Capital Management LLC. Company insiders that have bought Intec Pharma stock in the last two years include Anthony J Maddaluna and Jeffrey A Meckler. View Insider Buying and Selling for Intec Pharma.

How do I buy shares of Intec Pharma?

Shares of NTEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Intec Pharma's stock price today?

One share of NTEC stock can currently be purchased for approximately $0.49.

How big of a company is Intec Pharma?

Intec Pharma has a market capitalization of $16.08 million. The biotechnology company earns $-43,540,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis. Intec Pharma employs 70 workers across the globe.View Additional Information About Intec Pharma.

What is Intec Pharma's official website?

The official website for Intec Pharma is http://www.intecpharma.com/.

How can I contact Intec Pharma?

Intec Pharma's mailing address is 12 HARTOM STREET HAR HOTZVIM, JERUSALEM L3, 777512. The biotechnology company can be reached via phone at 972-2586-4657 or via email at [email protected]


MarketBeat Community Rating for Intec Pharma (NASDAQ NTEC)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  239 (Vote Outperform)
Underperform Votes:  271 (Vote Underperform)
Total Votes:  510
MarketBeat's community ratings are surveys of what our community members think about Intec Pharma and other stocks. Vote "Outperform" if you believe NTEC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTEC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel